"Messy compromise" on combo SPCs in EU could increase thickets and litigation
This article was originally published in SRA
More legal disputes between originators and generics companies could ensue if the Court of Justice of the European Union upholds the opinion1 of one of its advocates general on whether companies can get supplementary protection certificates on their combination drugs, according to one legal expert familiar with the case.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.